Aethlon Medical Announces Fiscal Q3 2026 Financial Results and Corporate Update

About this update from Aethlon Medical, Inc.

[{"type":"text","content":"Clinical and research programs continue to advance, supported by year-to-date cost efficiencies","length":95,"tagName":"p","attribs":{}},{"type":"text","content":"Conference Call Today at 4:30 p.m. ET","length":37,"tagName":"p","attribs":{}},{"type":"text","content":"SAN DIEGO, Feb. 12, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (the Company or Aethlon) (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal third quarter ended December 31, 2025, and provided an update on recent developments.","length":356,"tagName":"p"},{"type":"text","content":"Key Highlights","length":14,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Maintained Nasdaq Listing: Continued compliance with Nasdaq listing requirements, with all prior compliance matters remaining resolved.","length":135,"tagName":"p"}]},{"val":[{"type":"text","content":"Clinical Progress: Cohort 2 of the Australian oncology trial is actively progressing, reflecting continued clinical execution.","length":126,"tagName":"p"}]},{"val":[{"type":"text","content":"Scientific Advancement: Continued advancement of the Company's preclinical extracellular vesicle (EV) research platform, including Long COVID data published on bioRxiv and submitted for peer review, supporting the Hemopurifier's potential as a multi-indication therapeutic approach and a "pipeline within a single device".","length":340,"tagName":"p"}]},{"val":[{"type":"text","content":"Technology Development: Continued evaluation of Hemopurifier® (HP) compatibility with a simplified blood treatment system to support broader potential clinical application over time.","length":182,"tagName":"p"}]},{"val":[{"type":"text","content":"Operational Efficiency: Maintained disciplined cost controls, resulting in lower year-to-date operating expenses compared to prior year.","length":136,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":919,"olType":false},{"type":"text","content":"Clinical and Corporate Update","length":29,"tagName":"p"},{"type":"text","content":"Clinical Progress in Cancer Trial","length":33,"tagName":"p"},{"type":"text","content":"Enrollment and treatment of participants in Cohort 2 of the Australian oncology trial is actively underway, bui...

More updates from Aethlon Medical, Inc.